Jessica Ainscough is the Senior Director of Clinical Operations for Cambrian Bio. Ainscough brings over 17 years of experience in the industry as a dedicated clinical operations and quality management leader. She has held leadership roles in clinical operations at Epizyme, Kadmon Holdings and ICON and in compliance management at Tesaro and Beth Israel Deaconess Medical Center in which she developed risk management programs. Ainscough has been at the forefront of clinical operations design and development and strategically bringing early stage clinical assets through to FDA approval.

Eva Berggren is the Administrator and Executive Assistant to the CEO at Amplifier Therapeutics. She brings over 20 years experience of pre-clinical and clinical drug development from Betagenon AB. While there, she conitributed to laboratory work, pre-clinical drug development and assistance in clinical development. She brings a broad experience in pre-clinical drug development, clinical CRO management and team/Business administration. Berggren holds a MS in Biomedicin from University at Umeå, Sweden.

James Hall, MD, PhD, serves as a Scientific Advisor for Amplifier Therapeutics. Dr. Hall brings extensive senior healthcare and life science experience, including 12 years with AstraZeneca. While there, he held a number of commercial, R&D and Business Development roles, including VP Global Marketing for the CV/GI Therapy Area, Global Product VP for Crestor and VP Evaluation for the CV/Metabolism/Renal Therapy Area. Prior to this he was a member of the Pharmaceutical /Medical Products practice at McKinsey & Co. He has a BM, BCh in Clinical Medicine and a D.Phil in Cell Physiology from Oxford University, where he was a Rhodes Scholar.

Vrej Jubian, PhD, is a Director, API Manufacturing and Drug Product, CMC. With over 25 years of experience in pharmaceutical, biotech and chemical industries, he brings expertise in chemical development of small organic molecules from the discovery stage to the clinic. Prior to joining Cambrian, he served in the Business Management group at Thermo Fisher’s API drug substance division providing technical assessments and solutions for clients looking to develop their clinical candidates. Before Thermo Fisher, he worked as the CMC Manager for Synaptic Pharmaceuticals and subsequently as a Principal Scientist for Lundbeck. He managed outsourcing activities for development programs and internal medchem projects. He also headed a scale-up lab and provided leadership in drug discovery projects where his group identified several drug development candidates targeting novel GPCRs for CNS therapeutics. Jubian received his PhD in organic chemistry from McGill University (Montreal, Canada) and completed his postdoctoral training at University of Pittsburgh.

Claire O’Brien is Vice President of Research & Development Project Management at Cambrian Bio. She has 30 years of experience in developing medicines at Ipsen, GlaxoSmithKline (including Glaxo Wellcome and Glaxo Group Research), and in biotech, an in-depth knowledge of medicine development, and a track record in leading global, matrixed teams to advance programs through discovery, development, and launch. After earning a degree in chemistry at Kingston University London, she spent ten years in formulation and analytical development, then moved into cross-functional project leadership, working in multiple disease areas and with teams across US, EU, China, and Japan. Her deep interest in the development and growth of talent has been a theme throughout her career, and she has been coaching for 15 years with a particular interest in coaching scientists to lead.

Erik Schneider is Vice President of Business Development at Cambrian Bio. Previously, he was on the Business Development and Licensing team at Novartis, evaluating deal and portfolio strategy across cardiovascular, immunology, and neuroscience franchises. Prior to joining Novartis, Schneider was a consultant at CBPartners (now Trinity Life Sciences), with a focus on commercial and pricing strategy for new products. Schneider graduated from the College of the Holy Cross with a degree in Biochemistry.

Ruth Thieroff-Ekerdt, MD, is the Executive Vice President, Clinical Development at Cambrian Bio. Prior to joining Cambrian, she was Chief Medical Officer at Sojournix, and Acting CMO/Scientific Advisor at Organon. She also served as Chief Medical Officer at Aptalis, Strongbridge, Kaleido and held R& D positions of increasing responsibility at Bayer. She graduated as MD and Dr. med. from the Free University Berlin and specialized in Pharmacology and Clinical Pharmacology. She has over 30 years of experience in pharmaceutical R& D at all stages of discovery, development, and commercialization, with a successful track record of leading translational and development programs, submissions, and product launches in EU and US in various therapeutic areas and technologies. She also served as expert in the European Innovative Medicine Initiative and on the Scientific Advisory Board for Chr. Hansen. Dr. Thieroff-Ekerdt has published 28 scientific articles and conference contributions and is inventor/co-inventor of 31 patents.